News Sentiment

DCOY sentiment intelligence

Decoy Therapeutics Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed

Weighted score 50 Balanced news tone 31 relevant articles

Exchange NASDAQ United States

Sector Healthcare Market context

Industry Biotechnology Read-through group

Latest close 5.61 Week of 17 Jul 2026

Weighted tone 50/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

84/100 classification confidence.

Company focus 22

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-5.1% over one week, -7.6% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Decoy Therapeutics (DCOY) price target increased by 1,100.00% to 30.60

Market Reaction

Price moving ahead of tone

59/100 confidence

Primary event Market update 84/100 classification

One-week reaction -5.1% Price reacting lower

Trend fit Trend inactive -7.6% over four weeks

Fair value -22.2% Below fair value

Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance

Positive 1

Neutral 29

Negative 1

Relevance

Why the article matched

Direct first

Direct company coverage 22

Industry context 9

Sector context 0

Sources

Coverage mix

Publishers

Market source 7

PR Newswire 6

Moomoo 3

marketscreener.com 2

simplywall.st 2

TradingView 2

MarketBeat 2

MSN 1

Event Lens

What the news is about

Classified themes

Market update 20

Earnings 9

Analyst action 1

Guidance 1

Sentiment Trail

Score over time

50 baseline

Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 31

MSN Direct company coverage

Decoy Therapeutics (DCOY) price target increased by 1,100.00% to 30.60

Tone: Neutral 50/100
Event: Analyst action
Published: 21 Jul 2026 06:00
Source: MSN

Binance Direct company coverage

$5.86 | Decoy Therapeutics Inc. Common Stock (DCOY) Stock Price Today

Tone: Neutral 50/100
Event: Market update
Published: 18 Jul 2026 20:20
Source: Binance

Market source Industry context

Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks

Tone: Neutral 50/100
Event: Earnings
Published: 16 Jul 2026 18:49
Source: Market source

marketscreener.com Direct company coverage

Decoy Therapeutics Inc. Elects Patricia Gauthier as Class II Director

Tone: Neutral 50/100
Event: Market update
Published: 15 Jul 2026 17:35
Source: marketscreener.com

Investing.com Direct company coverage

Decoy Therapeutics elects Patricia Gauthier to board

Tone: Neutral 50/100
Event: Market update
Published: 15 Jul 2026 14:05
Source: Investing.com

Intellectia AI Direct company coverage

Decoy Therapeutics Appoints New Board Member

Tone: Neutral 50/100
Event: Market update
Published: 15 Jul 2026 13:59
Source: Intellectia AI

PR Newswire Direct company coverage

Decoy Therapeutics Stockholders Elect Patricia Gauthier to Board of Directors

Tone: Neutral 50/100
Event: Market update
Published: 15 Jul 2026 13:24
Source: PR Newswire

Kalkine Direct company coverage

Decoy Therapeutics Inc. (NASDAQ: DCOY) Share Price, DCOY Stock News, DCOY Share Price & Updates

Tone: Neutral 50/100
Event: Market update
Published: 14 Jul 2026 20:00
Source: Kalkine

Moomoo Direct company coverage

Decoy Therapeutics Company Profile & Introduction

Tone: Neutral 50/100
Event: Market update
Published: 13 Jul 2026 14:40
Source: Moomoo

Market source Industry context

Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks

Tone: Neutral 50/100
Event: Earnings
Published: 13 Jul 2026 07:00
Source: Market source

Moomoo Direct company coverage

Decoy Therapeutics (DCOY) Stock Forum and Discussion

Tone: Neutral 50/100
Event: Market update
Published: 11 Jul 2026 20:50
Source: Moomoo

marketscreener.com Direct company coverage

Decoy Therapeutics Files to Register Up to 3.77 Million Shares for Resale

Tone: Neutral 50/100
Event: Market update
Published: 10 Jul 2026 20:46
Source: marketscreener.com

Investing.com India Direct company coverage

Form S-1 Decoy Therapeutics Inc For: 10 July

Tone: Neutral 50/100
Event: Market update
Published: 10 Jul 2026 20:39
Source: Investing.com India

PR Newswire Direct company coverage

Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing

Tone: Neutral 50/100
Event: Market update
Published: 26 Jun 2026 07:00
Source: PR Newswire

PR Newswire Direct company coverage

Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London

Tone: Neutral 50/100
Event: Market update
Published: 08 Jun 2026 12:00
Source: PR Newswire

PR Newswire Direct company coverage

Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors

Tone: Neutral 50/100
Event: Market update
Published: 03 Jun 2026 12:00
Source: PR Newswire

PR Newswire Direct company coverage

Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the Clinic

Tone: Neutral 50/100
Event: Market update
Published: 01 Jun 2026 11:00
Source: PR Newswire

simplywall.st Industry context

There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings

Tone: Negative 34/100
Event: Earnings
Published: 15 May 2026 07:00
Source: simplywall.st

Market source Industry context

Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings

Tone: Neutral 50/100
Event: Earnings
Published: 14 May 2026 07:00
Source: Market source

simplywall.st Industry context

Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results

Tone: Positive 66/100
Event: Earnings
Published: 11 May 2026 07:00
Source: simplywall.st

Market source Industry context

Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00

Tone: Neutral 50/100
Event: Earnings
Published: 11 May 2026 07:00
Source: Market source

Market source Industry context

Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks

Tone: Neutral 50/100
Event: Earnings
Published: 25 Apr 2026 07:00
Source: Market source

Market source Industry context

Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)

Tone: Neutral 50/100
Event: Earnings
Published: 21 Apr 2026 07:00
Source: Market source

TradingView Industry context

A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack

Tone: Neutral 50/100
Event: Earnings
Published: 29 Mar 2026 07:00
Source: TradingView

Investing.com South Africa Direct company coverage

Decoy Therapeutics to implement 1-for-12 reverse stock split By Investing.com

Decoy Therapeutics Inc. announced a 1-for-12 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement. The split, effective Friday, will reduce outstanding shares and adjust options and warrants without altering ownership percentages. This move follows

Tone: Neutral 50/100
Event: Market update
Published: 10 Mar 2026 15:08
Source: Investing.com South Africa